Shares in West Pharmaceutical (NYSE:WST) fell today after the manufacturer missed sales estimates on Wall Street with its second quarter results.
The Exton, Penn.-based company posted profits of $38.8 million, or 51¢ per share, on sales of $397.6 million for the 3 months ended June 30, for bottom-line loss of -13% on sales growth of 2.5% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post West misses on sales, beats EPS in Q2 appeared first on MassDevice.